Chemical Technology

Specialty silicone components

May 6, 2022

Specialty silicone
For over 40 years, NuSil® has developed high-purity components for sophisticated silicone chemistries. Our deep expertise allows us to develop innovative chemistries that serve demanding requirements in multiple industries and applications.

Spotlight

Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our passionate team to keep doing these two things again and again as we continue to build a leading gastrointestinal therapeutics company. We discovered, developed and are commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). We are also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract. Our pipeline priorities include exploring further opportunities for our lead medicine, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to advance multiple investigational medicines. Ironwood was founded in 1998 out of the Whitehead Institute for B

OTHER WHITEPAPERS
news image

WHAT‘S NEW WITH FLARING IN 2022

whitePaper | September 1, 2022

Without exception, all industries are facing major challenges due to the volatile business environment in which we’ve all been operating since 2020.

Read More
news image

A New Standard in Passive Fire Protection (PFP) Coatings Performance

whitePaper | July 14, 2022

The hydrocarbon industry has strict international testing standards related to the performance of passive fire protective (PFP) coatings for oil and gas platforms, terminals, refineries and other petrochemical facilities.

Read More
news image

Why Deck 7

whitePaper | January 1, 2020

With over 2,800 campaigns each year delivered through a team of 300+ digital, data, and technology specialists, Deck 7 is a first resource for B2B demand generation services for marketers worldwide. Clients leverage Deck 7’s multichannel content marketing services and Media 7’s network of 30+ online publications for content syndication to engage over 95 million buyers across 16 industries and 120+ countries.

Read More
news image

Global Minimum Transparency Standard (GMTS)for hazardous chemicals in products

whitePaper | September 20, 2022

This white paper presents the case for a global standard requiring disclosure of hazardous chemicals used in a product in international trade.

Read More
news image

Carbon Capture and Storage, a necessary tool to fight climate change

whitePaper | June 16, 2022

Carbon Capture, Utilization and Storage (CCUS) covers all technologies dedicated to removing CO2 from flue gas, industrial gases, natural gas and the atmosphere,

Read More
news image

Green Chemistry and Contract Synthesis – a Contradiction?

whitePaper | June 17, 2021

The topic of green chemistry is now also a challenge for contract synthesis suppliers. This is because more and more manufacturers of shampoos, detergents, paints, packaging and other consumer products are becoming increasingly concerned about the ecological footprint of their products. The trend is being fueled by consumers, who are increasingly prepared to spend more money on products that are better for the environment. But the political environment is also exerting major pressure on companies.

Read More

Spotlight

Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our passionate team to keep doing these two things again and again as we continue to build a leading gastrointestinal therapeutics company. We discovered, developed and are commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). We are also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract. Our pipeline priorities include exploring further opportunities for our lead medicine, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to advance multiple investigational medicines. Ironwood was founded in 1998 out of the Whitehead Institute for B

Events